To include your compound in the COVID-19 Resource Center, submit it here.

Immune Design reports Phase II STS data for CMB305

Immune Design Corp. (NASDAQ:IMDZ) reported interim data from a Phase II trial evaluating CMB305 (ID-CMB305) plus Tecentriq atezolizumab compared to Tecentriq alone to treat soft tissue sarcoma (STS). In a prespecified interim analysis of 36 evaluable patients, CMB305

Read the full 383 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE